{
    "nct_id": "NCT06215118",
    "official_title": "A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA",
    "inclusion_criteria": "* Prior diagnosis of multiple myeloma as defined by IMWG criteria\n* Measurable disease based on IMWG criteria as defined by at least 1 of the following:\n* Serum M-protein ≥0.5 g/dL by SPEP\n* Urinary M-protein excretion ≥200 mg/24 hour by UPEP\n* Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (<0.26 or >1.65)\n* Part 1: Received 2-4 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.\n* Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.\n* ECOG performance status 0-1\n* Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome\n* Impaired cardiovascular function or clinically significant cardiovascular diseases\n* Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease\n* Participants with any active, uncontrolled bacterial, fungal, or viral infection\n* Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ\n* Previous treatment with:\n* BCMA-directed or CD3 redirecting therapy\n* Iberdomide (CC-220) or Mezigdomide\n* Administration of strong inhibitor or inducer of CYP3A4/5 within 2 weeks prior to dosing and during the study\n* Administration with an investigational product within 30 days preceding the first dose of study intervention\n* Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis",
    "miscellaneous_criteria": ""
}